Peter Rickenbacher
Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial.
Seeger J, Wöhrle J, Scheller B, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Weilenmann D, Stachel G, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Jeger R, On Behalf Of The Basket-Small Investigators. Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial. J Cardiovasc Dev Dis 2023; 10
Mar 13, 2023Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial.
Mar 13, 2023J Cardiovasc Dev Dis 2023; 10
Seeger Julia, Wöhrle Jochen, Scheller Bruno, Farah Ahmed, Ohlow Marc-Alexander, Mangner Norman, Möbius-Winkler Sven, Weilenmann Daniel, Stachel Georg, Leibundgut Gregor, Rickenbacher Peter, Cattaneo Marco, Gilgen Nicole, Kaiser Christoph A, Jeger Raban V, On Behalf Of The Basket-Small Investigators
Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2.
Mangner N, Farah A, Ohlow M, Möbius-Winkler S, Weilenmann D, Wöhrle J, Linke A, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Scheller B, Jeger R, BASKET-SMALL 2 Investigators. Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. Circ Cardiovasc Interv 2022; 15:e011325.
Jan 10, 2022Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2.
Jan 10, 2022Circ Cardiovasc Interv 2022; 15:e011325
Mangner Norman, Farah Ahmed, Ohlow Marc-Alexander, Möbius-Winkler Sven, Weilenmann Daniel, Wöhrle Jochen, Linke Axel, Stachel Georg, Markovic Sinisa, Leibundgut Gregor, Rickenbacher Peter, Cattaneo Marco, Gilgen Nicole, Kaiser Christoph, Scheller Bruno, Jeger Raban V, BASKET-SMALL 2 Investigators
Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial
Wöhrle J, Jeger R, Kaiser C, Gilgen N, Cattaneo M, Rickenbacher P, Leibundgut G, Stachel G, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, Seeger J, Scheller B, BASKET-SMALL 2 Investigators. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial. JACC Cardiovasc Interv 2021; 14:1789-1798.
Jan 23, 2021Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial
Jan 23, 2021JACC Cardiovasc Interv 2021; 14:1789-1798
Wöhrle Jochen, Jeger Raban V, Kaiser Christoph, Gilgen Nicole, Cattaneo Marco, Rickenbacher Peter, Leibundgut Gregor, Stachel Georg, Weilenmann Daniel, Möbius-Winkler Sven, Mangner Norman, Ohlow Marc-Alexander, Farah Ahmed, Seeger Julia, Scheller Bruno, BASKET-SMALL 2 Investigators
Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial
Jeger R, Scheller B, Kaiser C, Gilgen N, Cattaneo M, Osswald S, Rickenbacher P, Leibundgut G, Markovic S, Stachel G, Wöhrle J, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, BASKET-SMALL 2 Investigators. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2020; 396:1504-1510.
Oct 19, 2020Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial
Oct 19, 2020Lancet 2020; 396:1504-1510
Jeger Raban V, Scheller Bruno, Kaiser Christoph, Gilgen Nicole, Cattaneo Marco, Osswald Stefan, Rickenbacher Peter, Leibundgut Gregor, Markovic Sinisa, Stachel Georg, Wöhrle Jochen, Weilenmann Daniel, Möbius-Winkler Sven, Mangner Norman, Ohlow Marc-Alexander, Farah Ahmed, BASKET-SMALL 2 Investigators
Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial
Simonavičius J, van Empel V, Knackstedt C, Puronaitė R, Čelutkienė J, Pfisterer M, Kaufmann B, Pfister O, Maeder M, Rickenbacher P, Sanders van-Wijk S, Brunner-La Rocca H. Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. Am J Med 2019; 132:e679-e692.
Apr 30, 2019Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial
Apr 30, 2019Am J Med 2019; 132:e679-e692
Simonavičius Justas, van Empel Vanessa, Knackstedt Christian, Puronaitė Roma, Čelutkienė Jelena, Pfisterer Matthias, Kaufmann Beat A, Pfister Otmar, Maeder Micha, Rickenbacher Peter, Sanders van-Wijk Sandra, Brunner-La Rocca Hans-Peter
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuilliomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PloS one 2019; 14:e0210821.
Jan 15, 2019Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jan 15, 2019PloS one 2019; 14:e0210821
Jeger Raban V, Weilenmann Daniel, Rickli Hans, Hansen Kim Wadt, Rickenbacher Peter, Conen David, Müller Christian, Osswald Stefan, Gilgen Nicole, Vuilliomenet André, Pedrazzini Giovanni, Pfisterer Matthias, Vogt Deborah R, Galatius Søren, Abildgaard Ulrik, Naber Christoph, Alber Hannes, Eberli Franz, Kurz David J, Kaiser Christoph
Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial
Jeger R, Stephan F, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B, Linke A, Mahfoud F, Schreiber M, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet 2018; 392:849-856.
Aug 28, 2018Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial
Aug 28, 2018Lancet 2018; 392:849-856
Jeger Raban V, Stephan Frank-Peter, Mueller Christian, Rickenbacher Peter, Coslovsky Michael, Gilgen Nicole, Osswald Stefan, Kaiser Christoph, Scheller Bruno, Linke Axel, Mahfoud Felix, Schreiber Matthias, Farah Ahmed, Ohlow Marc-Alexander, Mangner Norman, Möbius-Winkler Sven, Leibundgut Gregor, Weilenmann Daniel, Wöhrle Jochen, Richter Stefan, BASKET-SMALL 2 Investigators
Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?
Steinmann E, Brunner-La Rocca H, Maeder M, Kaufmann B, Pfisterer M, Rickenbacher P. Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. Eur J Intern Med 2018
Jun 13, 2018Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?
Jun 13, 2018Eur J Intern Med 2018
Steinmann Eva, Brunner-La Rocca Hans-Peter, Maeder Micha, Kaufmann Beat A, Pfisterer Matthias, Rickenbacher Peter
Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine
Davarzani N, Brunner-La Rocca H, Peeters R, Pfisterer M, Zaugg C, Rolny V, Block D, de Boer R, Suter T, Karel J, Smirnov E, Rickenbacher P, Maeder M, Sanders-van Wijk S, TIME-CHF Investigators. Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine. EPMA J 2018; 9:161-173.
May 13, 2018Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine
May 13, 2018EPMA J 2018; 9:161-173
Davarzani Nasser, Brunner-La Rocca Hans-Peter, Peeters Ralf, Pfisterer Matthias E, Zaugg Christian, Rolny Vinzent, Block Dirk, de Boer Rudolf A, Suter Thomas, Karel Joël, Smirnov Evgueni, Rickenbacher Peter, Maeder Micha, Sanders-van Wijk Sandra, TIME-CHF Investigators
Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2
Gilgen N, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan F, Coslovsky M, Jeger R, Krackhardt F, Zweiker R, Farah A, Scheller B, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, BASKET-SMALL 2 Investigators. Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. Clin Cardiol 2018; 41:569-575.
May 10, 2018Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2
May 10, 2018Clin Cardiol 2018; 41:569-575
Gilgen Nicole, Butter Christian, Bruch Leonhard, Kaiser Christoph, Hoffmann Andreas, Rickenbacher Peter, Mueller Christian, Stephan Frank-Peter, Coslovsky Michael, Jeger Raban, Krackhardt Florian, Zweiker Robert, Farah Ahmed, Scheller Bruno, Ohlow Marc-Alexander, Mangner Norman, Weilenmann Daniel, Wöhrle Jochen, Jamshidi Peiman, Leibundgut Gregor, Möbius-Winkler Sven, BASKET-SMALL 2 Investigators
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Rickenbacher P, Kaufmann B, Maeder M, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca H. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017
Mar 15, 2017Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Mar 15, 2017Eur J Heart Fail 2017
Rickenbacher Peter, Kaufmann Beat A, Maeder Micha, Bernheim Alain, Goetschalckx Kaatje, Pfister Otmar, Pfisterer Matthias, Brunner-La Rocca Hans-Peter
N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF
Davarzani N, Peeters R, Rickenbacher P, Pfisterer M, Gutmann M, Leibundgut G, Maeder M, Karel J, Sanders-van Wijk S, Brunner-La Rocca H. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF. J Card Fail 2017; 23:382-389.
Feb 13, 2017N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF
Feb 13, 2017J Card Fail 2017; 23:382-389
Davarzani Nasser, Peeters Ralf, Rickenbacher Peter, Pfisterer Matthias E, Gutmann Marc, Leibundgut Gregor, Maeder Micha, Karel Joël, Sanders-van Wijk Sandra, Brunner-La Rocca Hans-Peter
Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF
Sanders-van Wijk S, Brunner-La Roccaenen H, Latini R, Rickli H, Tobler D, Tavazzi L, Gorini M, Rickenbacher P, Milani V, Masson S. Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. Clin Chem 2016; 62:605-16.
Mar 2, 2016Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF
Mar 2, 2016Clin Chem 2016; 62:605-16
Sanders-van Wijk Sandra, Brunner-La Roccaenen Hans-Peter, Latini Roberto, Rickli Hans, Tobler Daniel, Tavazzi Luigi T, Gorini Marco, Rickenbacher Peter, Milani Valentina, Masson Serge
Impact of worsening renal function related to medication in heart failure
Brunner-La Rocca H, Maeder M, Rickenbacher P, Tobler D, Pfisterer M, Krause F, Rolny V, Eurlings L, Knackstedt C, TIME‐CHF investigators. Impact of worsening renal function related to medication in heart failure. Eur J Heart Fail 2014; 17:159-68.
Dec 30, 2014Impact of worsening renal function related to medication in heart failure
Dec 30, 2014Eur J Heart Fail 2014; 17:159-68
Brunner-La Rocca Hans-Peter, Maeder Micha, Rickenbacher Peter, Tobler Daniel, Pfisterer Matthias E, Krause Friedemann, Rolny Vinzent, Eurlings Luc, Knackstedt Christian, TIME‐CHF investigators
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial
Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2014; 131:74-81.
Nov 19, 2014Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial
Nov 19, 2014Circulation 2014; 131:74-81
Kaiser Christoph, Vuillomenet André, Steiner Martin, von Felten Stefanie, Vogt Deborah R, Wadt Hansen Kim, Rickenbacher Peter, Conen David, Müller Christian, Buser Peter, Hoffmann Andreas, Pfisterer Matthias, Weilenmann Daniel, Rickli Hans, Galatius Soeren, Jeger Raban, Gilgen Nicole, Skov Jensen Jan, Naber Christoph, Alber Hannes, Wanitschek Maria, Eberli Franz, Kurz David J, Pedrazzini Giovanni, Moccetti Tiziano, BASKET-PROVE II study group
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF
Sanders-van Wijk S, Brunner-La Rocca H, Pfisterer M, Peter M, Rickenbacher P, Erne P, Estlinbaum W, Rickli H, Nietlispach F, Maeder M, TIME-CHF Investigators. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Circ Heart Fail 2013; 7:131-9.
Dec 18, 2013Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF
Dec 18, 2013Circ Heart Fail 2013; 7:131-9
Sanders-van Wijk Sandra, Brunner-La Rocca Hans-Peter, Pfisterer Matthias P, Peter Martin, Rickenbacher Peter, Erne Paul, Estlinbaum Werner, Rickli Hans, Nietlispach Fabian, Maeder Micha, TIME-CHF Investigators
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
Maeder M, Brunner-La Rocca H, Pfisterer M, Peter M, Vuilliomenet A, Erne P, Gutmann M, Abbühl H, Rickli H, Rickenbacher P, TIME-CHF Investigators. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail 2013; 15:1148-56.
May 8, 2013N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
May 8, 2013Eur J Heart Fail 2013; 15:1148-56
Maeder Micha, Brunner-La Rocca Hans-Peter, Pfisterer Matthias, Peter Martin, Vuilliomenet André, Erne Paul, Gutmann Marc, Abbühl Heidi, Rickli Hans, Rickenbacher Peter, TIME-CHF Investigators
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)
Sanders-van Wijk S, Brunner-La Rocca H, Pfisterer M, Peter M, Vuillomenet A, Rickenbacher P, Erne P, Estlinbaum W, Rickli H, van Asselt A, TIME-CHF Investigators. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC Heart Fail 2013; 1:64-71.
Feb 4, 2013Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)
Feb 4, 2013JACC Heart Fail 2013; 1:64-71
Sanders-van Wijk Sandra, Brunner-La Rocca Hans-Peter, Pfisterer Matthias E, Peter Martin, Vuillomenet André, Rickenbacher Peter, Erne Paul, Estlinbaum Werner, Rickli Hans, van Asselt Antoinette D I, TIME-CHF Investigators
End-of-life preferences of elderly patients with chronic heart failure
Brunner-La Rocca H, Rickli H, Pfisterer M, Osswald S, Pfister O, Leventhal M, Kiowski W, Jeker U, Maeder M, Schindler R, Muzzarelli S, Rickenbacher P, TIME-CHF Investigators. End-of-life preferences of elderly patients with chronic heart failure. Eur Heart J 2011; 33:752-9.
Nov 8, 2011End-of-life preferences of elderly patients with chronic heart failure
Nov 8, 2011Eur Heart J 2011; 33:752-9
Brunner-La Rocca Hans-Peter, Rickli Hans, Pfisterer Matthias E, Osswald Stefan, Pfister Otmar, Leventhal Marcia E, Kiowski Wolfgang, Jeker Urs, Maeder Micha, Schindler Ruth, Muzzarelli Stefano, Rickenbacher Peter, TIME-CHF Investigators
BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial
Pfisterer M, Brunner-La Rocca H, Schindler R, Hilti P, Schieber M, Osterhues H, Suter T, Yoon S, Beer H, Dubach P, Jeker U, Vuillomenet A, Rickenbacher P, Erne P, Gutmann M, Rickli H, Buser P, TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA : the journal of the American Medical Association 2009; 301:383-92.
Jan 28, 2009BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial
Jan 28, 2009JAMA : the journal of the American Medical Association 2009; 301:383-92
Pfisterer Matthias, Brunner-La Rocca Hans-Peter, Schindler Ruth, Hilti Patrick, Schieber Michael M, Osterhues Hans H, Suter Thomas, Yoon Se-Il, Beer Hansjürg, Dubach Paul, Jeker Urs, Vuillomenet André, Rickenbacher Peter, Erne Paul, Gutmann Marc, Rickli Hans, Buser Peter, TIME-CHF Investigators